IOB - Delayed Quote DKK

Novozymes A/S (0Q4U.IL)

482.95
-4.20
(-0.86%)
At close: June 13 at 5:36:55 PM GMT+1
Loading Chart for 0Q4U.IL
  • Previous Close 487.15
  • Open 482.65
  • Bid 475.50 x --
  • Ask 493.90 x --
  • Day's Range 482.65 - 488.30
  • 52 Week Range 368.60 - 488.97
  • Volume 79,077
  • Avg. Volume 292,730
  • Market Cap (intraday) 133.677B
  • Beta (5Y Monthly) 0.44
  • PE Ratio (TTM) 39.20
  • EPS (TTM) 12.32
  • Earnings Date Aug 21, 2025
  • Forward Dividend & Yield 10.20 (3.59%)
  • Ex-Dividend Date Oct 11, 2023
  • 1y Target Est 411.63

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

www.novozymes.com

6,852

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 0Q4U.IL

View More

Performance Overview: 0Q4U.IL

Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

0Q4U.IL
19.11%
OMX Copenhagen 25 Index (^OMXC25)
1.93%

1-Year Return

0Q4U.IL
18.81%
OMX Copenhagen 25 Index (^OMXC25)
9.62%

3-Year Return

0Q4U.IL
23.66%
OMX Copenhagen 25 Index (^OMXC25)
11.86%

5-Year Return

0Q4U.IL
40.43%
OMX Copenhagen 25 Index (^OMXC25)
37.16%

Compare To: 0Q4U.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0Q4U.IL

View More

Valuation Measures

Annual
As of 6/13/2025
  • Market Cap

    226.10B

  • Enterprise Value

    236.86B

  • Trailing P/E

    65.40

  • Forward P/E

    32.05

  • PEG Ratio (5yr expected)

    0.27

  • Price/Sales (ttm)

    7.50

  • Price/Book (mrq)

    2.68

  • Enterprise Value/Revenue

    7.83

  • Enterprise Value/EBITDA

    48.49

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.31%

  • Return on Assets (ttm)

    10.14%

  • Return on Equity (ttm)

    26.21%

  • Revenue (ttm)

    17.74B

  • Net Income Avi to Common (ttm)

    3.42B

  • Diluted EPS (ttm)

    12.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.05B

  • Total Debt/Equity (mrq)

    58.88%

  • Levered Free Cash Flow (ttm)

    1.02B

Research Analysis: 0Q4U.IL

View More

Company Insights: 0Q4U.IL

Research Reports: 0Q4U.IL

View More

People Also Watch